PolyPid Asset Resilience Ratio
PolyPid asset resilience ratio. PolyPid (PYPD) has an Asset Resilience Ratio of 29.28% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PolyPid defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PolyPid (2016–2025)
Asset resilience ratio of PolyPid from 2016 to 2025. This chart shows how PolyPid's Asset Resilience Ratio has changed over time. Read PYPD liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PolyPid's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PolyPid total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.53 Million | 29.28% |
| Total Liquid Assets | $6.53 Million | 29.28% |
Asset Resilience Insights
- Very High Liquidity: PolyPid maintains exceptional liquid asset reserves at 29.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PolyPid Industry Peers by Asset Resilience Ratio
Compare PolyPid's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
PolyPid Asset Resilience Ratio by Year (2016–2025)
PolyPid asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for PolyPid.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 29.28% | $6.53 Million | $22.31 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $15.37 Million | -- |
| 2022-12-31 | 15.56% | $4.04 Million | $25.97 Million | -35.04pp |
| 2021-12-31 | 50.60% | $22.38 Million | $44.23 Million | -2.34pp |
| 2020-12-31 | 52.94% | $40.16 Million | $75.85 Million | -14.24pp |
| 2019-12-31 | 67.18% | $22.68 Million | $33.77 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $14.48 Million | -- |
| 2017-12-31 | 61.05% | $14.03 Million | $22.98 Million | +21.90pp |
| 2016-12-31 | 39.14% | $7.53 Million | $19.24 Million | -- |
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more